Evidence Hub

A Phase I, Randomized, Gender Stratified, Double-Blind, Placebo- and Positive-Controlled, Three Period Crossover Trial to Assess the Effect of Guanfacine Hydrochloride on QT/QTc Interval in Healthy Men and Women

ClinicalTrials.gov · COMPLETED, 2008

83 participants

Abstract

To assess the effect of immediate-release guanfacine hydrochloride, administered at therapeutic and supratherapeutic doses, on QT/QTc in healthy normal males and females

Conditions: Healthy Volunteers.

Primary outcome: Change From Baseline in Electrocardiogram Results (QTcNi) at Time of Maximum Plasma Concentration (Tmax) on Day 1; Change From Baseline in Electrocardiogram Results (QTcNi) at Tmax on Day 6; Change From Baseline in Electrocardiogram Results (QTcF) at Tmax on Day 1; Change From Baseline in Electrocardiogram Results (QTcF) at Tmax on Day 6; Change From Baseline in Heart Rate (HR) at Tmax on Day 1; Change From Baseline in Heart Rate (HR) at Tmax on Day 6; Change From Baseline in Electrocardiogram Results (QT) Interval at Tmax on Day 1; Change From Baseline in Electrocardiogram Results (QT) Interval at Tmax on Day 6.

Enrollment: 83 participants.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 83 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free